Genetic variability can influence an individual's susceptibility to doxorubicin's toxic effects. Polymorphisms in genes encoding for enzymes involved in drug metabolism, such as cytochrome P450, and those related to oxidative stress response, can alter the risk profile. Pharmacogenomic testing is an emerging tool to identify patients at higher risk for toxicity.
